Sinovac’s 10 billion yuan plans include new facility, global HQ in Singapore: Lianhe Zaobao
Add BT as a preferred source
Tan Nai Lun
CHINESE vaccine maker Sinovac Biotech is investing 10 billion yuan (S$2 billion) in a development plan which includes opening a research facility and its international headquarters in Singapore, Lianhe Zaobao reported on Wednesday (Jun 15).
The research facility will develop vaccines for Covid-19 and severe hand, foot and mouth disease, and may be operational as early as within the next few months, said Helen Yang, Sinovac’s Hong Kong general manager and chief business officer.
She shared Sinovac’s plans in an interview with Zaobao last week, while in Singapore to discuss cooperation with local organisations. The 10 billion yuan figure includes opening a research facility in Singapore or collaborating with local research institutes to study new pathogens – though it is unclear exactly how much will be invested in Singapore itself.
TRENDING NOW
SIA sinks into the red with S$76 million Q1 loss as fuel costs jump
15-month wait-out curb lifted for private property owners buying HDB resale flats
ABSD deadline extended to up to 7 years for developers of large en bloc sites to encourage reuse of land
A ‘shadow bank’ hiding in Singapore’s Little India casts light on financial services gap
